HC Wainwright Brokers Decrease Earnings Estimates for OLMA

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Equities researchers at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.64) per share for the quarter, down from their prior estimate of ($0.58). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.44) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($2.36) EPS, FY2029 earnings at ($1.69) EPS and FY2030 earnings at ($1.03) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06).

A number of other brokerages have also weighed in on OLMA. Weiss Ratings lowered Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 3rd. Citigroup reduced their target price on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a report on Tuesday. Guggenheim lowered their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $10.44 on Thursday. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $11.24 and its two-hundred day moving average is $15.55. Olema Pharmaceuticals has a 12-month low of $5.13 and a 12-month high of $36.26. The stock has a market capitalization of $913.50 million, a price-to-earnings ratio of -4.92 and a beta of 2.03.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently modified their holdings of OLMA. EverSource Wealth Advisors LLC raised its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares during the period. Torren Management LLC purchased a new stake in Olema Pharmaceuticals during the fourth quarter worth approximately $44,000. Russell Investments Group Ltd. purchased a new stake in Olema Pharmaceuticals during the third quarter worth approximately $53,000. American Century Companies Inc. acquired a new stake in shares of Olema Pharmaceuticals in the second quarter worth $54,000. Finally, Quantbot Technologies LP acquired a new position in shares of Olema Pharmaceuticals during the second quarter worth about $77,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Insider Buying and Selling

In other news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the sale, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. This represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 12.56% of the stock is owned by company insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.